Ajai Chari, MD

Therapeutic Approaches for the Patient with Relapsed Myeloma

08/29/2020

Antibodies in Practice: SLAMF-7, CD38, Bispecific Updates: Should They be Used Upfront?

10/24/2019

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Primary Analysis

Purpose of the Study: Daratumumab (DARA), a human CD38 mAb, is approved as monotherapy and in combination with standard-of-care (SoC) regimens for MM. In phase 3 studies, DARA-based regim...

Larry D. Anderson Jr.;

Daniela Hoehn ;

Nitya Nathwani ;

Thomas S. Lin ;

Nina Shah ;

Paul G. Richardson ;

Yvonne A. Efebera ;

Caitlin L. Costello , MD;

Andrzej Jakubowiak ;

Tanya M. Wildes ;

Ajai Chari , MD;

Robert Z. Orlowski ;

Peter M. Voorhees , MD;

Kenneth G. Shain ;

Johnathan L. Kaufman ;

Ander J. Cowan ;

Jacob Laubach ;

Sean Murphy ;

Douglas W. Sborov ;

Yana Lutska ;

Brandi Reeves ;

Huiling Pei ;

Cesar Rodriguez ;

Jon Ukropec ;

Rebecca Silbermann ;

Jessica Vermeulen ;

Luciano J. Costa ;

Carla de Boer ;

10/22/2019

Videos

FDA Approval of GPRC5D-Targeting Bispecific Antibody Talquetamab for Patients With R/R MM

08/21/2023

Ajai Chari , MD;

Ajai Chari, MD, discusses the significance of the accelerated approval of talquetamab for the treatment of patients with R/R multiple myeloma, as well as offers advice for practicing oncologists regarding using this therapy.

Ajai Chari, MD, discusses the...

08/21/2023

Oncology